Immunotherapies: exploiting the immune system for cancer treatment

J Koury, M Lucero, C Cato, L Chang… - Journal of …, 2018 - Wiley Online Library
Cancer is a condition that has plagued humanity for thousands of years, with the first
depictions dating back to ancient Egyptian times. However, not until recent decades have …

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

JA McCubrey, LS Steelman, WH Chappell… - …, 2012 - pmc.ncbi.nlm.nih.gov
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic
alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK) …

Xanthohumol from Hop: Hope for cancer prevention and treatment

S Girisa, Q Saikia, D Bordoloi, K Banik, J Monisha… - IUBMB …, 2021 - Wiley Online Library
Cancer is a major public health concern due to high mortality and poor quality of life of
patients. Despite the availability of advanced therapeutic interventions, most treatment …

A pH-responsive yolk-like nanoplatform for tumor targeted dual-mode magnetic resonance imaging and chemotherapy

X Sun, R Du, L Zhang, G Zhang, X Zheng, J Qian… - ACS …, 2017 - ACS Publications
Incorporation of T1 and T2 contrast material in one nanosystem performing their respective
MR contrast role and simultaneously serving as an efficient drug delivery system (DDS) has …

Protein kinase Cδ suppresses autophagy to induce kidney cell apoptosis in cisplatin nephrotoxicity

D Zhang, J Pan, X **ang, Y Liu, G Dong… - Journal of the …, 2017 - journals.lww.com
Nephrotoxicity is a major adverse effect in cisplatin chemotherapy, and renoprotective
approaches are unavailable. Recent work unveiled a critical role of protein kinase Cδ …

DNA damage response in nephrotoxic and ischemic kidney injury

M Yan, C Tang, Z Ma, S Huang, Z Dong - Toxicology and Applied …, 2016 - Elsevier
DNA damage activates specific cell signaling cascades for DNA repair, cell cycle arrest,
senescence, and/or cell death. Recent studies have demonstrated DNA damage response …

Nanoparticle therapeutics: Technologies and methods for overcoming cancer

BBS Cerqueira, A Lasham, AN Shelling… - European Journal of …, 2015 - Elsevier
It is anticipated that by 2030 approximately 13 million people will die of cancer. Common
cancer therapy often fails due to the development of multidrug resistance (MDR), resulting in …

Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells

JM Hearn, I Romero-Canelón, AF Munro, Y Fu… - Proceedings of the …, 2015 - pnas.org
The organometallic “half-sandwich” compound [Os (η6-p-cymene)(4-(2-pyridylazo)-N, N-
dimethylaniline) I] PF6 is 49× more potent than the clinical drug cisplatin in the 809 cancer …

A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN)

J Guan, Q Li, Y Zhang, N **ao, M Chen, Y Zhang… - …, 2016 - pmc.ncbi.nlm.nih.gov
Purpose This study was performed to compare the efficacies and toxicities of cisplatin
(CDDP)-and carboplatin (CBDCA)-based chemotherapy (CT) in patients with SCCHN …

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian …

M Zanjirband, RJ Edmondson, J Lunec - Oncotarget, 2016 - pmc.ncbi.nlm.nih.gov
Ovarian cancer is the fifth leading cause of cancer-related female deaths. Due to serious
side effects, relapse and resistance to standard chemotherapy, better and more targeted …